Astrid P. Mckeown
Stevenage, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myeloma.
Journal: Haematologica
Published: May 08, 2026
Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 10, 2026
Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7.
Journal: British journal of cancer
Published: September 19, 2025
Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 08, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: April 28, 2025
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.
Journal: The Lancet. Haematology
Published: January 16, 2025
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Journal: The New England journal of medicine
Published: June 03, 2024
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Journal: The Lancet. Haematology
Published: May 25, 2023
The SECURE STAIRS Framework: Preliminary Evaluation of Trauma Informed Training Developments Within the Children and Young People's Secure Estate.
Journal: Community mental health journal
Published: October 17, 2022
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 12, 2022
Introduction of Technology to Support Young People's Care and Mental Health-A Rapid Evidence Review.
Introduction of Technology to Support Young People's Care and Mental Health-A Rapid Evidence Review.
Journal: Child & youth care forum
Published: June 08, 2022
Last Updated: 09/26/2026